The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

PNC-28

Off-label · Grade C

Goals
immune
Evidence
0 RCT / 1 animal / 8 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

PNC-27

Research chemical · Grade C

Goals
immune
Evidence
0 RCT / 3 animal / 12 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Dasatinib + Quercetin

Off-label · Grade C

Goals
healing, longevity, immune
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
oral
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
Half-life: 3-5 hours
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

FOXO4-DRI

Research chemical · Grade C

Goals
longevity, immune
Evidence
0 RCT / 2 animal / 4 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →